Pharmacologic treatments for covid-19 patients
Favipiravir Early vs Favipiravir Late
This comparison will not be updated. Last search date 14 Dec, 2022.
Hospitalized patients
Forest plots
(last update: 2021-06-10)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=92
Back to your research
Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | |||||||
jRCTs041190120 Doi Y, Antimicrob Agents Ch, 2020 Full text Commentary |
Mixed |
Favipiravir |
Favipiravir |
RCT | Patients with confirmed COVID-19 (asymptomatic-mild-moderate) admitted to multiple centers in Japan | N=89 |
Some concerns Details |